Bronchodilator Market Report: Trends, Forecast and Competitive Analysis to 2030
Get it in 2 to 4 weeks by ordering today
Bronchodilator Trends and Forecast
The future of the global bronchodilator market looks promising with opportunities in the sympathomimetic, anticholinergic, phosphodiesterase inhibitor, and combination drug markets. The global bronchodilator market is expected to reach an estimated $25.7 billion by 2030 with a CAGR of 3.0% from 2024 to 2030. The major drivers for this market are increasing prevalence of chronic respiratory disorders, rising pollution levels, and growing smoking-related health issues.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Bronchodilator by Segment
The study includes a forecast for the global bronchodilator by indication, route of administration, drug type, and region.
Bronchodilator Market by Indication [Shipment Analysis by Value from 2018 to 2030]:
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies bronchodilator companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the bronchodilator companies profiled in this report include-
Lucintel forecasts that asthma will remain the larger segment over the forecast period due to the notable global increase in the prevalence of asthma.
Within this market, anticholinergic will remain the largest segment due to its increasing adoption for treating chronic obstructive pulmonary disease.
North America will remain the largest region over the forecast period due to rise in government initiatives to raise awareness of asthma, and other chronic respiratory problems, as well as a notable increase in cystic fibrosis.
Features of the Global Bronchodilator Market
Market Size Estimates: Bronchodilator market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Bronchodilator market size by indication, route of administration, drug type, and region in terms of value ($B).
Regional Analysis: Bronchodilator market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different indication, route of administration, drug types, and regions for the bronchodilator market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the bronchodilator market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the bronchodilator market size?
Answer: The global bronchodilator market is expected to reach an estimated $25.7 billion by 2030.
Q2. What is the growth forecast for bronchodilator market?
Answer: The global bronchodilator market is expected to grow with a CAGR of 3.0% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the bronchodilator market?
Answer: The major drivers for this market are increasing prevalence of chronic respiratory disorders, rising pollution levels, and growing smoking-related health issues.
Q4. What are the major segments for bronchodilator market?
Answer: The future of the bronchodilator market looks promising with opportunities in the sympathomimetic, anticholinergic, phosphodiesterase inhibitor, and combination drug markets.
Q5. Who are the key bronchodilator market companies?
Answer: Some of the key bronchodilator companies are as follows:
Answer: Lucintel forecasts that asthma will remain the larger segment over the forecast period due to the notable global increase in the prevalence of asthma.
Q7. In bronchodilator market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to rise in government initiatives to raise awareness of asthma, and other chronic respiratory problems, as well as a notable increase in cystic fibrosis.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the bronchodilator market by indication (asthma, chronic obstructive pulmonary disease, and others), route of administration (oral, injection, and inhaler), drug type (sympathomimetics, anticholinergics, phosphodiesterase inhibitor, combination drugs, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Bronchodilator Market, Bronchodilator Market Size, Bronchodilator Market Growth, Bronchodilator Market Analysis, Bronchodilator Market Report, Bronchodilator Market Share, Bronchodilator Market Trends, Bronchodilator Market Forecast, Bronchodilator Companies, write Lucintel analyst at email: [email protected]. We will be glad to get back to you soon.
Bronchodilator Trends and Forecast
The future of the global bronchodilator market looks promising with opportunities in the sympathomimetic, anticholinergic, phosphodiesterase inhibitor, and combination drug markets. The global bronchodilator market is expected to reach an estimated $25.7 billion by 2030 with a CAGR of 3.0% from 2024 to 2030. The major drivers for this market are increasing prevalence of chronic respiratory disorders, rising pollution levels, and growing smoking-related health issues.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Bronchodilator by Segment
The study includes a forecast for the global bronchodilator by indication, route of administration, drug type, and region.
Bronchodilator Market by Indication [Shipment Analysis by Value from 2018 to 2030]:
- Asthma
- Chronic Obstructive Pulmonary Disease
- Others
- Oral
- Injection
- Inhaler
- Sympathomimetics
- Anticholinergics
- Phosphodiesterase Inhibitor
- Combination Drugs
- Others
- North America
- Europe
- Asia Pacific
- The Rest of the World
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies bronchodilator companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the bronchodilator companies profiled in this report include-
- F. Hoffmann-La Roche
- AstraZeneca
- Novartis
- Pfizer
- Teva Pharmaceutical
- Vectura Group
- Abbott Laboratories
Lucintel forecasts that asthma will remain the larger segment over the forecast period due to the notable global increase in the prevalence of asthma.
Within this market, anticholinergic will remain the largest segment due to its increasing adoption for treating chronic obstructive pulmonary disease.
North America will remain the largest region over the forecast period due to rise in government initiatives to raise awareness of asthma, and other chronic respiratory problems, as well as a notable increase in cystic fibrosis.
Features of the Global Bronchodilator Market
Market Size Estimates: Bronchodilator market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Bronchodilator market size by indication, route of administration, drug type, and region in terms of value ($B).
Regional Analysis: Bronchodilator market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different indication, route of administration, drug types, and regions for the bronchodilator market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the bronchodilator market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the bronchodilator market size?
Answer: The global bronchodilator market is expected to reach an estimated $25.7 billion by 2030.
Q2. What is the growth forecast for bronchodilator market?
Answer: The global bronchodilator market is expected to grow with a CAGR of 3.0% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the bronchodilator market?
Answer: The major drivers for this market are increasing prevalence of chronic respiratory disorders, rising pollution levels, and growing smoking-related health issues.
Q4. What are the major segments for bronchodilator market?
Answer: The future of the bronchodilator market looks promising with opportunities in the sympathomimetic, anticholinergic, phosphodiesterase inhibitor, and combination drug markets.
Q5. Who are the key bronchodilator market companies?
Answer: Some of the key bronchodilator companies are as follows:
- F. Hoffmann-La Roche
- AstraZeneca
- Novartis
- Pfizer
- Teva Pharmaceutical
- Vectura Group
- Abbott Laboratories
Answer: Lucintel forecasts that asthma will remain the larger segment over the forecast period due to the notable global increase in the prevalence of asthma.
Q7. In bronchodilator market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to rise in government initiatives to raise awareness of asthma, and other chronic respiratory problems, as well as a notable increase in cystic fibrosis.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the bronchodilator market by indication (asthma, chronic obstructive pulmonary disease, and others), route of administration (oral, injection, and inhaler), drug type (sympathomimetics, anticholinergics, phosphodiesterase inhibitor, combination drugs, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Bronchodilator Market, Bronchodilator Market Size, Bronchodilator Market Growth, Bronchodilator Market Analysis, Bronchodilator Market Report, Bronchodilator Market Share, Bronchodilator Market Trends, Bronchodilator Market Forecast, Bronchodilator Companies, write Lucintel analyst at email: [email protected]. We will be glad to get back to you soon.
1. EXECUTIVE SUMMARY
2. GLOBAL BRONCHODILATOR MARKET : MARKET DYNAMICS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Bronchodilator Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Bronchodilator Market by Indication
3.3.1: Asthma
3.3.2: Chronic Obstructive Pulmonary Disease
3.3.3: Others
3.4: Global Bronchodilator Market by Route of Administration
3.4.1: Oral
3.4.2: Injection
3.4.3: Inhaler
3.5: Global Bronchodilator Market by Drug Type
3.5.1: Sympathomimetics
3.5.2: Anticholinergics
3.5.3: Phosphodiesterase Inhibitor
3.5.4: Combination Drugs
3.5.5: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030
4.1: Global Bronchodilator Market by Region
4.2: North American Bronchodilator Market
4.2.1: North American Bronchodilator Market by Indication: Asthma, Chronic Obstructive Pulmonary Disease, and Others
4.2.2: North American Bronchodilator Market by Drug Type: Sympathomimetics, Anticholinergics, Phosphodiesterase Inhibitor, Combination Drugs, and Others
4.3: European Bronchodilator Market
4.3.1: European Bronchodilator Market by Indication: Asthma, Chronic Obstructive Pulmonary Disease, and Others
4.3.2: European Bronchodilator Market by Drug Type: Sympathomimetics, Anticholinergics, Phosphodiesterase Inhibitor, Combination Drugs, and Others
4.4: APAC Bronchodilator Market
4.4.1: APAC Bronchodilator Market by Indication: Asthma, Chronic Obstructive Pulmonary Disease, and Others
4.4.2: APAC Bronchodilator Market by Drug Type: Sympathomimetics, Anticholinergics, Phosphodiesterase Inhibitor, Combination Drugs, and Others
4.5: ROW Bronchodilator Market
4.5.1: ROW Bronchodilator Market by Indication: Asthma, Chronic Obstructive Pulmonary Disease, and Others
4.5.2: ROW Bronchodilator Market by Drug Type: Sympathomimetics, Anticholinergics, Phosphodiesterase Inhibitor, Combination Drugs, and Others
5. COMPETITOR ANALYSIS
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Bronchodilator Market by Indication
6.1.2: Growth Opportunities for the Global Bronchodilator Market by Route of Administration
6.1.3: Growth Opportunities for the Global Bronchodilator Market by Drug Type
6.1.4: Growth Opportunities for the Global Bronchodilator Market by Region
6.2: Emerging Trends in the Global Bronchodilator Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Bronchodilator Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Bronchodilator Market
6.3.4: Certification and Licensing
7. COMPANY PROFILES OF LEADING PLAYERS
7.1: F. Hoffmann-La Roche
7.2: AstraZeneca
7.3: Novartis
7.4: Pfizer
7.5: Teva Pharmaceutical
7.6: Vectura Group
7.7: Abbott Laboratories
2. GLOBAL BRONCHODILATOR MARKET : MARKET DYNAMICS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2018 TO 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Bronchodilator Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Bronchodilator Market by Indication
3.3.1: Asthma
3.3.2: Chronic Obstructive Pulmonary Disease
3.3.3: Others
3.4: Global Bronchodilator Market by Route of Administration
3.4.1: Oral
3.4.2: Injection
3.4.3: Inhaler
3.5: Global Bronchodilator Market by Drug Type
3.5.1: Sympathomimetics
3.5.2: Anticholinergics
3.5.3: Phosphodiesterase Inhibitor
3.5.4: Combination Drugs
3.5.5: Others
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION FROM 2018 TO 2030
4.1: Global Bronchodilator Market by Region
4.2: North American Bronchodilator Market
4.2.1: North American Bronchodilator Market by Indication: Asthma, Chronic Obstructive Pulmonary Disease, and Others
4.2.2: North American Bronchodilator Market by Drug Type: Sympathomimetics, Anticholinergics, Phosphodiesterase Inhibitor, Combination Drugs, and Others
4.3: European Bronchodilator Market
4.3.1: European Bronchodilator Market by Indication: Asthma, Chronic Obstructive Pulmonary Disease, and Others
4.3.2: European Bronchodilator Market by Drug Type: Sympathomimetics, Anticholinergics, Phosphodiesterase Inhibitor, Combination Drugs, and Others
4.4: APAC Bronchodilator Market
4.4.1: APAC Bronchodilator Market by Indication: Asthma, Chronic Obstructive Pulmonary Disease, and Others
4.4.2: APAC Bronchodilator Market by Drug Type: Sympathomimetics, Anticholinergics, Phosphodiesterase Inhibitor, Combination Drugs, and Others
4.5: ROW Bronchodilator Market
4.5.1: ROW Bronchodilator Market by Indication: Asthma, Chronic Obstructive Pulmonary Disease, and Others
4.5.2: ROW Bronchodilator Market by Drug Type: Sympathomimetics, Anticholinergics, Phosphodiesterase Inhibitor, Combination Drugs, and Others
5. COMPETITOR ANALYSIS
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Bronchodilator Market by Indication
6.1.2: Growth Opportunities for the Global Bronchodilator Market by Route of Administration
6.1.3: Growth Opportunities for the Global Bronchodilator Market by Drug Type
6.1.4: Growth Opportunities for the Global Bronchodilator Market by Region
6.2: Emerging Trends in the Global Bronchodilator Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Bronchodilator Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Bronchodilator Market
6.3.4: Certification and Licensing
7. COMPANY PROFILES OF LEADING PLAYERS
7.1: F. Hoffmann-La Roche
7.2: AstraZeneca
7.3: Novartis
7.4: Pfizer
7.5: Teva Pharmaceutical
7.6: Vectura Group
7.7: Abbott Laboratories
